I think a nice upfront payment and then ongoing revenue somewhere between 15-20% ... as many have re-iterated on here, Starpharma have taken Vivagel for BV through to phase III and now commercialisation on their own, so IMO judging from their negotiating capabilities with the Agrochem sale, we won't be disappointed in the outcome
Vivagel BV treatment and prevention, page-5
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.7¢ |
Change
-0.003(3.00%) |
Mkt cap ! $40.48M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.0¢ | 9.7¢ | $38.11K | 389.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20455 | 9.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 38876 | 3 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| SPL (ASX) Chart |